Abstract：
Cow\'s milk allergy (CMA) is an abnormal immune response that severely affects the nutritional supplementation of allergic infants. Currently, only a limited number of hypoallergenic formulas are available on the market, and these are only categorized according to their degree of hydrolysis, which still poses an allergy risk and cannot be consumed by CMA patients, especially infants. To address this issue, we developed a two-step hydrolysis hypoallergenic formula targeting destruction of allergen epitope from whey protein. Then, a comprehensive evaluation system was constructed, including peptidomics analysis, in vivo and in vitro allergenicity assessments, revealing allergic changes in the product from the epitope structure level to the immunological level. The results showed that 97.14% of hydrolyzed peptides from α-lactalbumin and β-lactoglobulin did not contain allergenic epitopes after treatment with trypsin and flavourzyme. In vitro and in vivo allergenicity assessment results confirmed that the two-step hydrolysis method effectively reduced the allergenicity of whey protein. Compared with the common milk powder, the hypoallergenic formula induced lower levels of basophil degranulation and relieved the body\'s anaphylactic symptoms caused by cow milk. This study provides a promising solution to the limited hypoallergenic formula problem and may benefit allergic infants who require nutritional supplements.
摘要：
牛奶过敏（CMA）是一种异常的免疫反应，严重影响过敏婴儿的营养补充。目前,市场上只有数量有限的低过敏性配方，这些仅根据其水解程度进行分类，仍然存在过敏风险，不能被CMA患者食用，尤其是婴儿。为了解决这个问题，我们开发了一种两步水解低变应原配方，旨在破坏乳清蛋白的变应原表位。然后，构建了一个综合评价体系，包括肽酶分析，体内和体外变应原性评估，揭示产品从表位结构水平到免疫学水平的过敏性变化。结果表明，用胰蛋白酶和风味酶处理后，97.14％的α-乳白蛋白和β-乳球蛋白水解肽不含有致敏性表位。体外和体内变应原性评估结果证实，两步水解方法有效降低了乳清蛋白的变应原性。与普通奶粉相比，这种低变应原性配方可诱导较低水平的嗜碱性粒细胞脱颗粒，缓解牛奶引起的身体过敏症状。这项研究为有限的低变应原性配方问题提供了一个有希望的解决方案，并可能使需要营养补充剂的过敏婴儿受益。
